Cargando…
Effect of the GLP-1 receptor agonist semaglutide on metabolic disturbances in clozapine-treated or olanzapine-treated patients with a schizophrenia spectrum disorder: study protocol of a placebo-controlled, randomised clinical trial (SemaPsychiatry)
INTRODUCTION: Clozapine and olanzapine are some of the most effective antipsychotics, but both are associated with weight gain and relevant metabolic disturbances, including pre-diabetes and diabetes. Non-pharmacological/behavioural interventions have had limited effects counteracting these adverse...
Autores principales: | Sass, Marie Reeberg, Danielsen, Andreas Aalkjær, Köhler-Forsberg, Ole, Storgaard, Heidi, Knop, Filip K, Nielsen, Mette Ødegaard, Sjödin, Anders Mikael, Mors, Ole, Correll, Christoph U, Ekstrøm, Claus, Vinberg, Maj, Nielsen, Jimmi, Vilsbøll, Tina, Fink-Jensen, Anders |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9890830/ https://www.ncbi.nlm.nih.gov/pubmed/36720576 http://dx.doi.org/10.1136/bmjopen-2022-068652 |
Ejemplares similares
-
A Pharmacological and Clinical Overview of Oral Semaglutide for the Treatment of Type 2 Diabetes
por: Andersen, Andreas, et al.
Publicado: (2021) -
T10. BIOMARKERS IN TREATMENT-RESISTANT SCHIZOPHRENIA; THE BITS STUDY (A STUDY PROTOCOL)
por: Hilker, Rikke, et al.
Publicado: (2020) -
The ins and outs of acid–base transport in skeletal muscle
por: Aalkjær, Christian, et al.
Publicado: (2018) -
Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin – a case series
por: Prasad, Femin, et al.
Publicado: (2023) -
SARS-CoV-2 seroprevalence among patients with severe mental illness: A cross-sectional study
por: Sass, Marie Reeberg, et al.
Publicado: (2022)